When the medication isn't working
Switching From Semaglutide to Tirzepatide: What to Ask
Switching from semaglutide to tirzepatide is common, but the labels give no switching schedule. Here is what the head-to-head trial found, how clinicians approach the change, and the questions to ask before your first dose.
Last reviewed
The Vital angle
Vital keeps every dose in one history, with the medication, amount, strength, source type, and date, so the last semaglutide dose and the first tirzepatide dose sit in the same record. Reminders help with the new weekly schedule, and your weight trend from Apple Health shows how the switch is going at your follow-up.
Switching from semaglutide to tirzepatide is a common medication change in weight care. People switch because weight loss stalled, side effects were hard, a pharmacy or insurer changed coverage, or a supply ran short. The change can work well, but it raises real questions: which dose to start, when to take the first shot, and what side effects to expect. This guide explains what is known and gives you a list of questions for your prescriber.
It covers Wegovy® and Ozempic® (semaglutide) and Zepbound® and Mounjaro® (tirzepatide), brand or compounded. Only your prescriber can plan the switch. Do not start, overlap, or change doses on your own.
How the two medicines differ
Both are once-weekly injections that act on the GLP-1 receptor, which lowers appetite and slows stomach emptying. Tirzepatide also acts on a second receptor, GIP. It has a half-life of about five to six days, according to the Zepbound label.
The SURMOUNT-5 trial compared the two directly in 751 adults with obesity and without type 2 diabetes. Over 72 weeks, at the highest tolerated dose of each, average weight loss was about 20 percent with tirzepatide and about 14 percent with semaglutide. Stomach side effects were common in both groups. About 5.6 percent of people stopped semaglutide because of them, compared with 2.7 percent on tirzepatide.
That is an average across a group. It does not predict what will happen for you, and it does not mean semaglutide failed if it worked for you.
Reasons people switch, and what each means
The reason for the switch shapes the plan:
- Weight loss stalled at a full semaglutide dose. This is the most common reason. Read GLP-1 stopped working first, since a plateau may be maintenance, not failure.
- Side effects on semaglutide. Some people tolerate tirzepatide better, but there is no guarantee. Nausea, diarrhea, and constipation happen with both.
- Cost, coverage, or supply. A practical switch may be more about access than results. See GLP-1 shortage.
- Leaving a compounded product. See compounded vs brand semaglutide for why product quality matters.
The labels do not give a switching schedule
Neither the Wegovy nor the Zepbound label includes a plan to move from one to the other. The Zepbound label sets one starting dose for all uses: 2.5 mg once weekly for four weeks, then 5 mg, then 2.5 mg steps after at least four weeks at each dose. It also says not to use tirzepatide with any other GLP-1 medicine. A 2026 expert-consensus review noted that no guidelines exist for this switch and that prospective switching trials are still needed.
In practice, clinicians use different approaches:
- Start at 2.5 mg, following the label, whatever the prior semaglutide dose.
- Start at a higher step for people who already tolerate a high semaglutide dose. The 2026 expert-consensus review proposed approximate matched dose bands for this approach. A case series of 10 people with type 2 diabetes also used a set protocol to switch from other GLP-1 medicines to tirzepatide.
- Escalate faster than usual after a low start. A small retrospective study of 15 people with type 2 diabetes looked at this after semaglutide 1 mg.
These are small studies and expert opinion, not a standard for everyone. The right plan depends on your dose, side effects, other medicines, and health history.
Timing the first tirzepatide dose
The labels do not say when to take the first tirzepatide dose after the last semaglutide dose. Because the Zepbound label advises against using tirzepatide with another GLP-1 medicine, the timing is a decision to make with your prescriber. Ask for the exact date in writing.
Things to tell your prescriber about timing:
- The date and dose of your last semaglutide injection.
- Any missed weeks in the past month, which can lower your tolerance.
- Whether you have semaglutide pens or vials left, and what to do with them.
Do not take both in the same week, and do not take leftover semaglutide after you switch unless your prescriber tells you to.
What to expect in the first weeks
If you start at a low tirzepatide dose after a high semaglutide dose, appetite may feel louder for a few weeks. That does not mean tirzepatide is not working. It means the dose is still low. See tirzepatide not working for the full timeline.
If you start at a higher dose, stomach side effects can be stronger at first. Plan smaller meals, drink enough fluids, and keep notes. See GLP-1 nausea relief and GLP-1 constipation.
New pens also work differently. A Zepbound single-dose pen, a Mounjaro KwikPen, and a compounded vial each have their own steps. Read the instructions for use, and see injection technique.
Questions to ask before you switch
Write these down and bring them to the appointment:
- Why are we switching, and what result would count as success?
- Which tirzepatide dose will I start on, and why?
- On which day do I take the first dose, and when was my last semaglutide dose?
- How fast will the dose go up, and what happens if side effects are hard?
- Do any of my other medicines need a change, such as insulin or a sulfonylurea?
- I use oral birth control. The Zepbound label advises a non-oral or added barrier method for four weeks after starting and after each dose increase. What should I use?
- Will my insurance or pharmacy cover tirzepatide, and is a prior authorization needed?
- If I use a compounded product, how many syringe units equal my dose?
- When is my follow-up, and what should I track until then?
Keep a clean record of the change
A switch is the moment when records get confusing. Note the last semaglutide dose and date, the first tirzepatide dose and date, every dose step after that, side effects, and your weekly weight average. This record helps your prescriber judge the switch at your follow-up. If you also change tracker apps, see switch GLP-1 tracker app.
When to get care now
Get medical help right away for:
- Severe stomach pain that does not go away, sometimes spreading to your back, with or without vomiting.
- Vomiting or diarrhea that stops you from keeping fluids down, or signs of dehydration.
- Swelling of the face, lips, or throat, or trouble breathing.
- Pain in the upper right stomach, fever, or yellow skin or eyes.
- Signs of low blood sugar if you also take insulin or a sulfonylurea.
Also tell your care team before any surgery or procedure that needs anesthesia or deep sedation.
Wegovy® and Ozempic® are trademarks of Novo Nordisk A/S. Mounjaro® and Zepbound® are trademarks of Eli Lilly and Company. Vital is independent and not affiliated with these companies.
Things to watch
Practical flags drawn from prescribing information and clinical guidance. Vital surfaces these in the dose log to help you spot them early.
Taking semaglutide and tirzepatide in the same week
The Zepbound label says not to use tirzepatide with any other GLP-1 medicine. Ask your prescriber for the exact date of the first tirzepatide dose.
Using an online conversion chart as a dose plan
The labels include no switching schedule, and published approaches come from small studies and expert opinion. Your starting dose is a prescriber decision.
Expecting full effect at 2.5 mg after a high semaglutide dose
The label says 2.5 mg is a starting dose and is not approved for maintenance. Appetite can feel louder for a few weeks until the dose rises.
Oral birth control during the switch
The Zepbound label advises a non-oral or added barrier method for four weeks after starting and after each dose increase.
Leftover semaglutide pens or vials
Using leftover semaglutide after the switch risks overlapping two GLP-1 medicines. Ask your prescriber or pharmacist what to do with them.
Frequently asked questions
The Zepbound label starts everyone at 2.5 mg, and it has no switching schedule. Some clinicians start higher for people who tolerate a high semaglutide dose. Your prescriber decides based on your dose and side effects.
The labels do not say. The Zepbound label advises against using tirzepatide with another GLP-1 medicine, so ask your prescriber for the exact date of your first dose.
In the SURMOUNT-5 trial, average weight loss over 72 weeks was about 20 percent with tirzepatide and about 14 percent with semaglutide. Results vary from person to person.
Stomach side effects such as nausea, diarrhea, and constipation are common with both. They can be stronger if you start tirzepatide at a higher dose. Smaller meals and fluids help, and your prescriber can adjust the pace.
If you start at 2.5 mg after a high semaglutide dose, the new dose may be weaker at first. Appetite often settles as the dose rises. Tell your prescriber if it does not.
No. Online charts come from indirect comparisons, not switching trials. Only your prescriber can plan the switch and the starting dose.
Sources
- A Study of Tirzepatide in Participants With Obesity or Overweight With Weight Related Comorbidities (SURMOUNT-5) · ClinicalTrials.gov
- SURMOUNT-5: Greater Loss of Weight, Waist Circumference With Tirzepatide Than Semaglutide · American College of Cardiology
- Zepbound (tirzepatide) Prescribing Information · Eli Lilly and Company
- Safety and Efficacy of Switching Patients With Type 2 Diabetes From Glucagon-Like Peptide-1 Receptor Agonists to Tirzepatide: A Case Series · NIH / NCBI
- Early Dose Escalation of Tirzepatide after Switching from Semaglutide in Type 2 Diabetes Mellitus · PubMed
- Switching between semaglutide and tirzepatide in obesity management: an expert-consensus framework · Expert Opinion on Pharmacotherapy
This page summarizes publicly available information from the sources listed above and is for educational use only. It is not medical advice. Consult a qualified healthcare professional for personal dosing guidance.
Track every shot, every change
Vital logs every GLP-1 injection and peptide dose, then surfaces patterns your scale can't show. Free on iOS and Android.
More from the Library
Compounded vs Brand Semaglutide
Compounded semaglutide and brand-name Wegovy or Ozempic are not the same product. A clear-eyed look at the actual differences in regulation, formulation, cost, and risk.
Food Noise Coming Back on a GLP-1: End-of-Week Hunger and What to Track
Food noise coming back on a GLP-1 can follow the dose week, a dose step, stress, or a product change. Here is what is known, what to track for two to four weeks, and what to ask your prescriber.
Tirzepatide Medication Level Chart: Half-Life, Steady State, and Missed Doses
A tirzepatide medication level chart and a semaglutide level chart built from label half-lives, with tables for one dose, the build-up to steady state, the weekly rise and fall, and a missed dose.
GLP-1 Not Working in the First Month: What Is Normal
Little or no weight loss in the first month on a GLP-1 is common, because the starting doses are low by design. Here is what the first weeks are for, what to watch, and when to call your prescriber.